Department of Internal Medicine, Regions Hospital, St Paul, MN, USA.
Am J Med. 2012 Mar;125(3):265-9. doi: 10.1016/j.amjmed.2011.08.022.
Arthrocentesis and joint injections are commonly performed for both diagnostic and therapeutic indications. Because of safety concerns, there is often reluctance to perform these procedures in patients who are receiving anticoagulation at therapeutic levels. This study was undertaken to determine the safety of arthrocentesis and joint injection performed by physicians from different disciplines in patients who are anticoagulated.
We conducted a retrospective review of 640 arthrocentesis and joint injection procedures performed in 514 anticoagulated patients between 2001 and 2009. We assessed the incidence of early and late clinically significant bleeding in or around a joint, infection, and procedure-related pain. We further compared the incidence of these complications in 456 procedures performed in patients with an international normalized ratio 2.0 or greater and 184 procedures performed in patients with an international normalized ratio less than 2.0.
Only 1 procedure (0.2%) resulted in early, significant, clinical bleeding in the fully anticoagulated group. There was no statistically significant difference in early and late complications between patients who had procedures performed with an international normalized ratio 2.0 or greater and those whose anticoagulation was adjusted to an international normalized ratio less than 2.0.
Arthrocentesis and joint injections in patients receiving chronic warfarin therapy with therapeutic international normalized ratio are safe procedures. There does not seem to be a need for reducing the level of anticoagulation before procedures in these patients.
关节穿刺术和关节内注射常用于诊断和治疗目的。由于安全方面的考虑,对于正在接受治疗剂量抗凝治疗的患者,通常不愿意进行这些操作。本研究旨在确定不同专业的医生在接受抗凝治疗的患者中进行关节穿刺术和关节内注射的安全性。
我们回顾性分析了 2001 年至 2009 年间 514 例接受抗凝治疗的患者中进行的 640 例关节穿刺术和关节内注射操作。我们评估了关节内或周围早期和晚期临床显著出血、感染和与操作相关的疼痛的发生率。我们进一步比较了国际标准化比值为 2.0 或更高的 456 例操作和国际标准化比值小于 2.0 的 184 例操作的这些并发症的发生率。
在完全抗凝组中,仅有 1 例(0.2%)发生早期、显著的临床出血。在国际标准化比值为 2.0 或更高的患者和将抗凝调整至国际标准化比值小于 2.0 的患者之间,早期和晚期并发症无统计学差异。
对于正在接受慢性华法林治疗且国际标准化比值处于治疗范围内的患者,关节穿刺术和关节内注射是安全的操作。似乎没有必要在这些患者进行操作前降低抗凝水平。